<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-82616</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cáncer</dc:title>
<dc:description xml:lang="en">OBJECTIVES: To determine the frequency of primary circulating prostate cells in men with prostate cancer at the time of diagnosis, the association with micrometastasis, sub-classification for CD82 and the relation with pathological stage. To determine their clinical usefulness to identify patients in whom radical prostatectomy would be first choice therapy.METHODS: Men with the diagnosis of prostate cancer before definitive therapy. Blood and bone marrow samples were taken, mononuclear cells separated by differential centrifugation and prostate cells identified with immunocytochemistry using anti-PSA. Positive samples were sub-classified with anti-CD82. Details of serum PSA, Gleason score and pathological stage were registered.RESULTS: Of 77 men 58 (75.3%) had primary CPCs detected, there was an association with stage but not Gleason. 31 (40.3%) had micrometastasis with an association with stage and Gleason score. CPC-negative patients had fewer micrometastasis detected, 1/19 versus 30/58 (p&lt;0.003).There was an inverse relation between CD82 expression and Gleason score, men with CPCs expressing CD82 had fewer micrometastasis. The combined group of CPC negative and CPC positive CD82 positive men showed a sensitivity of 87% and specificity of 73.9% for the absence of micrometastasis.CONCLUSIONS: The detection of CPCs and sub-classification with CD82 could be clinically useful to identify men with a significantly lower risk of micrometastais and as a consequence to identify men in whom radical prostatectomy could be the best initial treatment(AU)</dc:description>
<dc:creator>Badínez, Leonardo</dc:creator>
<dc:creator>Fuentealba, Cinthia</dc:creator>
<dc:creator>Murray, Nigel P</dc:creator>
<dc:creator>Dueñas, Ricardo</dc:creator>
<dc:creator>Orellana, Nelson</dc:creator>
<dc:creator>Reyes, Eduardo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">CONCLUSIONES: La presencia de CPCs implica un riesgo mayor de desarrollar micrometástasis, la co-expresión del CD82 es asociada con tumores de bajo grado, un riesgo disminuido del desarrollo de micrometástasis óseas. Como consecuencia, el uso de la detección de CPCs primarias y su sub-clasificación podrían ser clínicamente útiles para identificar los pacientes los cuales beneficiarán de una prostatectomía radical como tratamiento de primera línea(AU)</dc:description>
<dc:source>Arch Esp Urol;63(5): 345-353, jun. 2010. ilus, tab</dc:source>
<dc:identifier>ibc-82616</dc:identifier>
<dc:title xml:lang="es">Deteccion y características de células prostáticas circulantes primarias, asociación con la presencia de micrometástasis y las implicaciones para el tratamiento quirúrgico en hombres con cáncer prostático. El estudio ProTECT (Prostate Tumor Early Cancer Test)</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11911^s22074</dc:subject>
<dc:subject>^d51088^s22002</dc:subject>
<dc:subject>^d11914^s22053</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22921^s22074</dc:subject>
<dc:subject>^d30596^s22002</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d9555^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201006</dc:date>
</metadata>
</record>
</ibecs-document>
